Psilocybin Lowered Inflammation in 12 Parkinson Patients. Nobody Was Blinded
A UCSF team measured inflammation in the blood of people with Parkinson’s before and after psilocybin, and the markers went down. NPR covered it on Tuesday, as the first human signal behind fifteen years of animal work. The cohort is twelve people, and nobody was blinded.
Questions like this one arrive whether or not you offer the treatment. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The new paper | A blood-marker analysis published in JAMA Psychiatry on October 21 |
| The cohort | The same 12 Parkinson’s patients from an open-label UCSF pilot |
| The dosing | One 10 mg psilocybin session, then one 25 mg session, with psychotherapy |
| What moved | Five inflammatory signaling molecules fell against baseline and stayed down at one month |
| What did not | A mitochondrial stress marker improved immediately, then did not hold |
| The limit | No control group, and every participant knew what they received |
What Was Actually Measured
The team drew blood before and after psilocybin and tracked five signaling molecules involved in inflammation. They also tracked one marker of mitochondrial stress.
Inflammation was significantly lower after treatment than at baseline. Those changes were still present a month after the final dose.
The mitochondrial marker is the part most coverage will skip. It improved right after dosing and did not hold at the longer follow-up.
That split matters. One finding persisted and one did not, and a write-up that reports only the first is not reporting the study.
Twelve People, and Not a Random Twelve
The blood work comes from a cohort already described in the literature. The parent trial was an open-label pilot published in Neuropsychopharmacology last year.
It enrolled 12 people with mild to moderate Parkinson’s plus depression or anxiety. Mean age was 63, and five were women.
Each received one 10 mg psilocybin session followed by one 25 mg session, with psychotherapy around both.
That trial existed because people with neurodegenerative disease are normally excluded from psychedelic research on safety grounds. Getting them dosed at all was the point of it.
It reported no serious adverse events and no worsening of Parkinson’s symptoms. Ten of the twelve had treatment-emergent effects, most often anxiety, nausea and raised blood pressure.
The Design Problem, Stated Plainly
There was no control group. Every participant knew they were receiving psilocybin, and so did the people assessing them.
Unblinded biomarkers in twelve people are exactly the conditions under which expectancy and regression to the mean produce impressive-looking movement.
The authors say so themselves. One of the senior authors told NPR the blood findings need confirmation before anyone makes definitive claims.
Worth holding that next to the parent trial’s own symptom results, which showed very large effect sizes under the same open-label conditions. Large effects in small unblinded trials are the norm, not the exception.
Why It Is Still a Real Result
The hypothesis is not new, and that is what gives this weight. Psychedelics bind serotonin 5-HT2A receptors, and those receptors sit on cells far outside the brain.
Charles Nichols at LSU Health Sciences Center, whose lab found the anti-inflammatory effect in cell culture about fifteen years ago, called this a proof of principle to NPR. He did not work on the study.
His group has since run animal models in asthma, arthritis and cardiovascular disease. What the field lacked was any human data at all.
Previous human work on inflammation markers after psilocybin largely used healthy volunteers. These were patients with an actual inflammatory disease.
The Detail With Commercial Consequences
Nichols has reported the anti-inflammatory effect at doses well below the threshold for a psychoactive experience.
If that holds in humans, the therapeutic target separates from the trip entirely. No monitored room, no chair time, no certified setting.
That is the same direction we covered in our piece on the race to shorten chair time, and in the mouse study where a non-hallucinogenic version also worked.
None of which is close to a product. It is the reason pharmaceutical attention is pointed here.
What to Tell a Patient Who Brings This In
They will, and soon. An NPR segment about psychedelics and inflammation travels well past the people it describes.
What is supportable: twelve Parkinson’s patients showed lower inflammatory markers after psilocybin, and the change persisted a month.
What is not: that psilocybin treats inflammatory disease, or that this says anything about arthritis, long COVID or any condition the study did not enroll.
Worth adding that psilocybin remains Schedule I. There is no legal clinical route outside a trial, and this cohort was dosed with psychotherapy and medical supervision throughout.
We have covered the related ketamine work, where immune markers predicted who would respond, in our piece on immune signatures before a first dose.
A Signal, Not a Finding
One of the UCSF authors described it as an initial biological signal to investigate. That is the right size for what twelve unblinded patients can support.
The useful question is not whether this proves anything. It is whether a controlled trial follows, and how quickly.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical advice. Psilocybin is a Schedule I substance under federal law and is not an approved treatment for Parkinson’s disease or for any inflammatory condition.
